Your browser doesn't support javascript.
loading
Effects of IAT and MAT chemotherapeutic regimens in patients with refractory or relapsed acute myeloid leukemia / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 884-888, 2012.
Artigo em Chinês | WPRIM | ID: wpr-278472
ABSTRACT
The aim of this study was to investigate effects of IAT and MAT chemotherapeutic regimens treating patients with refractory and relapsed acute myeloid leukemia (AML). 99 patients with refractory and relapsed AML received IAT regimen or MAT regimen as study objects were retrospectively analyzed (56 patients with refractory AML and 43 patients with relapsed AML). Among of them, 28 patients were treated with IAT regimen, and 71 patients received with MAT regimen. The results showed that in 2 groups mentioned above the OR was 65.7%, CR was 49.5%, PR was 16.2%; in IAT group the OR was 64.3%, CR was 46.4%; in MAT group the OR was 66.2%, CR was 50.7%, no statistical difference was found between these 2 groups; The 2 years overall survival was 25% in IAT group and 15.5% in MAT group. Serious infection in IAT and MAT regime groups was 25% and 9.9%, respectively. It is concluded that both IAT and MAT regimens are effective methods for inducing CR in patients with refractory of relapsed AML. IAT and MAT regimens can be used in treatment of the refractory or relapsed MAL patients who were not respond to other regimen.
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Recidiva / Vidarabina / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Estudos Retrospectivos / Fator Estimulador de Colônias de Granulócitos / Citarabina / Usos Terapêuticos / Tratamento Farmacológico Tipo de estudo: Estudo observacional Limite: Adolescente / Adulto / Idoso / Criança / Feminino / Humanos / Masculino Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2012 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Recidiva / Vidarabina / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Estudos Retrospectivos / Fator Estimulador de Colônias de Granulócitos / Citarabina / Usos Terapêuticos / Tratamento Farmacológico Tipo de estudo: Estudo observacional Limite: Adolescente / Adulto / Idoso / Criança / Feminino / Humanos / Masculino Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2012 Tipo de documento: Artigo